Novel combination of immunotherapy with targeted drugs, including programmed death-1 (PD-1) inhibitor, cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) inhibitor and PARP Inhibitors and immunotherapy, can improve response and reduce resistance for patients with bladder cancer [31]. This evidence concerns the gene CTLA4 and urinary bladder cancer.